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Abstract
Background: Trimethylation of lysine 27 on histone H3 (H3K27me3) by enhancer of zeste
homolog 2 (EZH2) is an epigenetic mark that mediates gene silencing. EZH2 is overexpressed and
correlates with poor prognosis in many cancers. However, the clinical implication of H3K27me3 in
human malignancies has not been well established. We wished to ascertain whether a correlation
exists between the expression of H3K27me3 and clinical outcome in a group of patients with
esophageal squamous cell carcinoma (ESCC) treated with definitive chemoradiotherapy (CRT).
Methods: The method of immunohistochemistry (IHC) was utilized to examine the protein
expression of H3K27me3 in 98 pretreatment biopsy specimens of ESCC and in 30 samples of
normal esophageal mucosa. The clinical/prognostic significance of H3K27me3 expression was
statistically analyzed.
Results: The expression frequency and expression levels of H3K27me3 were significantly higher
in ESCCs than in normal tissues. There was a positive correlation between H3K27me3 expression
and WHO grade (P = 0.016), tumor size (P = 0.019), T status (P = 0.024), locoregional progression
(P = 0.009) and EZH2 expression (P = 0.036). High H3K27me3 expression was associated with
poor locoregional progression-free survival (LPFS) (P  = 0.010) in ESCC. Further analysis
demonstrated that H3K27me3 could stratify patient outcome in T2-3 (P = 0.048), N0 (P = 0.005)
and M0 (P = 0.018) stages as well as in CRT effective group (P = 0.022).
Conclusions: Our data suggests that H3K27me3 expression examined by IHC might be useful for
stratifying LPFS for different subsets of ESCC patients treated with definitive CRT.
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Background
Esophageal squamous cell carcinoma (ESCC) is an aggres-
sive human cancer with poor prognosis worldwide [1].
Most patients present with locally advanced disease, and
definitive chemoradiotherapy (CRT) is an important com-
ponent of the therapeutic strategy for ESCC [2]. Despite
the great advances achieved in radiotherapy technology
recently, its overall 5-year survival rate remains less than
30%, and the high probability of recurrence is still the
main cause of poor quality of life and death [3]. At
present, only the stage based on Tumor Node Metastases
(TNM) classification and primary complete response to
CRT are widely accepted as prognostic factors [4]. How-
ever, there are substantial differences in survival within
patients with the same clinical stage and/or CRT response,
probably attributable to the differences in biologic behav-
ior of the tumors. Improved prognostic markers that can
further stratify patient outcome are therefore needed.
It is known that epigenetic changes, including DNA meth-
ylation and covalent histone modification, are involved in
tumorigenesis and tumor progression of human cancers
[5,6]. One of the most important mechanisms is that
many cancer-related genes are silenced by the enhancer of
zeste homolog 2 (EZH2), which can specially trimethylate
lysine 27 on histone H3 (H3K27) of the target gene pro-
moters [7]. EZH2 is overexpressed and correlates with
poor prognosis in many cancers [8-13], however, the sta-
tus of H3K27 methylation and its clinical implication in
cancer patients are rarely studied. To date, the role of tri-
methylated H3K27 (H3K27me3) expression in patient
outcome for different types of human cancer is still elusive
[8,14,15], further investigations in different cohorts of
cancer patients are actually needed. Thus, we performed
the present study to investigate the clinical/prognostic
implication of H3K27me3 in ESCC patients treated with
definitive CRT.
Methods
Patients and tissue specimens
Ninety-eight primary ESCC patients treated with defini-
tive CRT were consecutively selected from the Department
of Radiotherapy, Cancer Center, Sun Yat-Sen University
between January 2002 and December 2008. Tumor grade
and stage were defined according to the 6th edition of the
TNM classification of the International Union Against
Cancer (UICC, 2002). Clinicopathologic characteristics
are summarized in Table 1. Patients with distant metas-
tases except for supraclavicular or celiac lymph nodes
were excluded from this study. All the patients received
the same PF regimen (Cisplatin 80 mg/m2 i.v. drip day 1,
28; 5-fluorouracil 3 g/m2 c.i.v. day 1 to 2, 28 to 29) con-
currently with radiotherapy (60-70 Gy, 1.8-2 Gy/fraction,
5 days a week). The tumor biopsy specimens were
recruited from paraffin blocks of the 98 primary ESCCs
from the Department of Pathology of our institutes. In
addition, 30 biopsy samples of normal esophageal
mucosa from the same patients from regions that were not
affected were used for controls. The study was approved
by the medical ethics committee of our institute.
Evaluation and follow-up
The effect of CRT was evaluated clinically for primary
lesions based on esophagography and computed tomog-
raphy (CT) 4 weeks after CRT according to World Health
Organization (WHO) criteria. Complete response (CR),
partial response (PR), no change (NC), and progressive
disease (PD) were achieved in 19 patients, 42 patients, 36
patients and 1 patient, respectively. Thus, 61 cases were
included in the effective group (CR/PR), the remaining 37
cases were included in the resistant group (NC/PD).
The patients were followed every 3 month for the first year
and then every 6 months for the next 2 years, and finally
annually. Of the 79 patients who didn't get CR, 22 cases
received adjuvant chemotherapy, 2 cases received radical
esophagectomy. The other patients didn't receive any anti-
tumor treatments until tumor progression. The diagnostic
examinations consisted of esophagography, CT, chest x-
ray, abdominal ultrasonography and bone scan when nec-
essary to detect recurrence and/or metastasis. Locore-
gional progression was defined as cases in which the
primary tumor and regional enlarged lymph nodes evalu-
ated as PD after CRT or recurrence after CR. Distant pro-
gression was defined as a failure control of the distant
metastatic lymph nodes and/or a new distant metastasis
occurred.
Immunohistochemistry (IHC)
IHC staining was performed on 5-μm tissue sections rehy-
drated through graded alcohols. Endogenous peroxidase
activity was blocked with 0.3% hydrogen peroxide for 15
min. For antigen retrieval, tissue slides were boiled in 10
mM citrate buffer (pH 6.0) and microwave-treated for 10
min (H3K27me3), or in tris (hydroxymethyl) ami-
nomethane-EDTA buffer (pH 8.0) in a pressure cooker for
12 min (EZH2). Nonspecific binding was blocked with
10% normal rabbit serum for 20 min. The tissue slides
were incubated with anti-H3K27me3 (Abcam, Cam-
bridge, MA, 1:50 dilution) or anti-EZH2 (BD Transduc-
tion Laboratories, Franklin Lakes, NJ, 1:100 dilution) for
60 min at 37°C in a moist chamber. Subsequently, the
slides were sequentially incubated with biotinylated rab-
bit antimouse immunoglobulin at a concentration of
1:100 for 30 min at 37°C and then reacted with a strepta-
vidin-peroxidase conjugate for 30 min at 37°C and 3'-3'
diaminobenzidine as a chromogen substrate. The nucleus
was counterstained using Meyer's hematoxylin. A negative
control was obtained by replacing the primary antibody
with a normal murine IgG. Positive expression ofBMC Cancer 2009, 9:461 http://www.biomedcentral.com/1471-2407/9/461
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H3K27me3 and EZH2 in ESCC and normal esophageal
mucosa cells was primarily a nuclear pattern (Fig. 1).
Known immunostaining positive slides were used as pos-
itive controls.
Two independent observers blinded to the clinicopatho-
logic information performed the scoring of H3K27me3
[14,15] and EZH2 [16-18] expression using their previ-
ously validated scoring systems respectively. For
H3K27me3, the system calculated the percentage of
nuclei staining positive for the H3K27me3 protein as
close as to the multiples of 10. Since the frequency for the
percentage of positively stained cells in all tumor samples
assessed for H3K27me3 was almost a normal distribution
with a range from 0% to 100%, and the median value was
50%, thus, categories of high and low expression were
defined as groups with percentage of positive cells above
or below/equal to 50% [14,15]. For EZH2, the system
scores nuclear EZH2 expression by recording the percent-
age of nuclei staining positive for the EZH2 protein, in
which EZH2 immunoreactivity was classified into two
groups: low expression, when positive cells were less than
50%; and high expression, when at least 50% of the cells
showed positive immunoreactivity in the nuclei [16-18].
In this study, a minimum of 500 epithelial cells was
counted for each normal or tumor case.
Statistical analysis
Statistical analysis was performed with the SPSS software
(SPSS Standard version 13.0, SPSS Inc.). The association
of H3K27me3 expression with ESCC patient's clinico-
pathologic features was assessed by the Chi-square test.
Locoregional progression-free survival (LPFS) was defined
as the time from diagnosis to tumor locoregional progres-
Table 1: H3K27me3 expression and clinicopathologic variables (Chi-square test)
H3K27me3 expression (%)
Variables Case low high P
Age (years) 0.255
≤55a 54 32(59.3) 22(40.7)
>55 44 21(47.7) 23(52.3)
Gender 0.720
Male 82 45(54.9) 37(45.1)
Female 16 8(50.0) 8(50.0)
Location 0.341
Cervical 24 15(62.5) 9(37.5)
Thoracic 74 38(51.4) 36(48.6)
WHO grade 0.016
G1 24 16(66.7) 8(33.3)
G2 50 30(60.0) 20(40.0)
G3-4 24 7(29.2) 17(70.8)
Tumor size (cm) 0.019
≤6b 56 36(64.3) 20(35.7)
>6 42 17(40.5) 25(59.5)
T status 0.024
T2-3 47 31(66.0) 16(34.0)
T4 51 22(43.1) 29(56.9)
N status 0.929
N0 16 8(50.0) 8(50.0)
N1 82 40(48.8) 42(51.2)
M status 0.651
M0 59 33(55.9) 26(44.1)
M1-lymc 39 20(51.3) 19(48.7)
CRT response 0.094
Effective 61 37(60.7) 24(39.3)
Resistant 37 16(43.2) 21(56.8)
Locoregional progression 0.009
Absent 51 34(66.7) 17(33.3)
Present 47 19(40.4) 28(59.6)
Distant progression 0.299
Absent 62 36(58.1) 26(41.9)
Present 36 17(47.2) 19(52.8)
aMean age. bMean tumor size. cDistant lymph node metastasis.BMC Cancer 2009, 9:461 http://www.biomedcentral.com/1471-2407/9/461
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Immunohistochemical stainings of H3K27me3 in human esophageal tissues Figure 1
Immunohistochemical stainings of H3K27me3 in human esophageal tissues. (A) A normal esophageal mucosa (case 
13) showed low expression of H3K27me3 protein, in which less than 50% of normal esophageal squamous cells showed posi-
tive staining of H3K27me3 in nuclei (200×). (B) An ESCC case (case 21) demonstrated low expression of H3K27me3, in which 
less than 50% of squamous cell carcinoma cells showed positive staining of H3K27me3 protein in nuclei (200×). (C) High 
expression of H3K27me3 was observed in an ESCC (case 39), where more than 70% carcinoma cells demonstrated positive 
staining of H3K27me3 in nuclei (200×). (D) A primary ESCC (case 52) was observed high expression of H3K27me3, where 
more than 90% carcinoma cells showed positive staining of H3K27me3 protein in nuclei (200×). (E) Another ESCC (case 7) 
was observed high expression of EZH2, where more than 90% of carcinoma cells showed positive staining of EZH2 protein in 
nuclei (400×). (F) High expression of H3K27me3 (more than 80% of carcinoma cells showed positive expression of 
H3K27me3) was observed in the same ESCC case 7 (400×). (G) For the 53 ESCC cases with high EZH2 expression, an average 
of 55.0% of the ESCC cells stained positive with H3K27me3 antibody, a percentage of cancer cells that was significantly larger 
than that (43.3%) in the remaining 45 cancers with a low expression of EZH2 (P = 0.036, independent sample t test).BMC Cancer 2009, 9:461 http://www.biomedcentral.com/1471-2407/9/461
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sion (the first end-point) or cancer-relative death (the sec-
ond end-point). Disease-specific survival (DSS) was
defined as the time from diagnosis to cancer-relative
death. LPFS and DDS were assessed with the Kaplan-Meier
method and compared by the log rank test. Multivariate
survival analysis was performed on all the parameters that
were found to be significant on univariate analysis using
the Cox regression model. An independent sample t test
was used to assess the expression of H3K27me3 between
groups with low and high expression of EZH2. P values of
< 0.05 were considered significant.
Results
Expression of H3K27me3 in ESCC
In the present study, protein expression of H3K27me3
was examined by IHC in 98 cases of primary ESCC and in
30 cases of normal esophageal mucosa. H3K27me3 was
detected in 85.7% (84/98) of ESCCs, whereas in normal
esophageal tissues the expression of H3K27me3 (19/30)
was significantly lower (63.3%, P = 0.007). Using the cri-
teria described above, high expression of H3K27me3 was
observed in 45.9% (45/98) of the ESCCs and only 20.0%
(6/30) of the normal esophageal tissues (P = 0.011). The
association between clinicopathologic features and
H3K27me3 expression levels of the 98 ESCCs were sum-
marized in Table 1. The expression of H3K27me3 corre-
lated closely with WHO grade (P = 0.016), tumor size (P
= 0.019) and T status (P = 0.024). No significant associa-
tion was found between CRT response and H3K27me3
expression (P = 0.094) or any clinicopathologic variables,
such as patient's age, gender and tumor grade, location,
size, T status and radiotherapy dose (60GY vs. > 60GY) (P
> 0.05).
Correlation between clinicopathologic variables, 
H3K27me3 expression and ESCC patient survival
Of the 98 ESCC patients, none was lost to follow-up. The
median observation period was 23.9 months (2.3-80.7
months), with 47 tumor locoregional progressions, 36
distant progressions and 68 cancer-related deaths. The 5-
year LPFS and DSS for the entire cohort of patients were
18.5% and 22.1%, respectively.
A positive association between high expression of
H3K27me3 and the present of locoregional progression
was demonstrated by our Chi-square test (Table 1). In
univariate analysis, although there was no significant dif-
ference in DSS between groups with high and low expres-
sion of H3K27me3 (median 20.0 vs. 22.6 months, P =
0.151), high H3K27me3 expression was evaluated to cor-
relate closely with poor LPFS (P = 0.010) for the ESCC
patients (Fig. 2, Table 2). In stratified survival analysis,
H3K27me3 expression could differentiate LPFS of the
patients in T2-3, N0 and M0 stages, as well as in CRT effec-
tive group (Fig. 2, Table 2), however, no stratified signifi-
cance of H3K27me3 expression was observed in DSS (P >
0.05).
Kaplan-Meier analysis also demonstrated a significant
impact of certain clinicopathologic prognostic parameters
such as T status (P = 0.002), CRT response (P 0.001) and
M-lym status (P = 0.043) on LPFS. No significant associa-
tion was found between survival and other clinicopatho-
logic variables, including radiotherapy dose and receiving
adjuvant chemotherapy or not (P > 0.05). The parameters
that were significant in univariate analysis were further
examined in multivariate analysis. The results showed
that T status, CRT response and M-lym status were inde-
pendent predictors of LPFS, while H3K27me3 expression
only showed a borderline significance (P = 0.065, Table
3).
Correlation between the expression of H3K27me3 and 
EZH2 in ESCCs
Using the criteria described above, high expression of
EZH2 was observed in 53/98 (54.1%) of the ESCCs (Fig.
1F) , the other 45 cases showed low expression of EZH2
(datas in submission). Thus, we further evaluated the rela-
tionship between the expression of H3K27me3 and
EZH2. The results showed a positive correlation between
the expression levels of H3K27me3 and EZH2. In the 53
ESCC cases with high EZH2 expression, an average of
55.0% of the ESCC cells stained positively with
H3K27me3 antibody, a percentage of cancer cells that was
significantly larger than that (43.3%) in the remaining 45
cancers with a low expression of EZH2 (P = 0.036, Fig.
1G).
Discussion
Since ESCC patients with the same TNM stage and/or CRT
response often display considerable variability in disease
progression and survival, the traditional grading system
may have reached its limits in providing critical informa-
tion influencing patient prognosis and treatment strate-
gies. Thus, novel diagnostic and risk assessment are
urgently needed. Recently, histone modification, which is
important for normal cell growth, has become an increas-
ingly important aspect of cancer biology [6,19-21]. One
such modification, the trimethylation of lysine 27 on his-
tone H3 (H3K27me3) is required for Polycomb Repres-
sive Complex 2 (PRC2) mediated repression of a large
number of genes essential for cell proliferation, cell differ-
entiation and tumor development [22,23]. It is believed
that maintenance of the H3K27me3 mark during cell divi-
sion is essential for normal embryogenesis and for pre-
serving cell identity [24,25]. In human cancer, H3K27me3
has been evaluated as a prognostic factor in prostate,
breast, ovarian, pancreatic and esophageal cancers
[8,14,15], however, some of the results are totally contra-
dictory. In the present study, we examined the expressionBMC Cancer 2009, 9:461 http://www.biomedcentral.com/1471-2407/9/461
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of H3K27me3, in 30 samples of normal esophageal
mucosa and 98 biopsy specimens of primary ESCCs
treated with definitive CRT.
Our results showed that a significant percentage of the
normal esophageal mucosa was observed positive stain-
ing of H3K27me3. However, the frequency of positive
expression and levels of H3K27me3 in our ESCC cohorts
were significant higher than that in normal esophageal tis-
sues. Further analysis demonstrated that high expression
of H3K27me3 was associated closely with poor tumor dif-
ferentiation and advanced local invasion in ESCC, which
was in general agreement with findings revealed by Ching
et al [15]. In addition, we did further found that
H3K27me3 expression correlated significantly with tumor
locoregional progression rather than distant metastasis.
These findings provide evidence that the up-regulation of
H3K27me3 may provide a selective advantage for carcino-
genesis and tumor progression of ESCC.
When focus on locoregional progression-free survival
(LPFS) of ESCC, we found that high expression of
H3K27me3 correlated with poor prognosis. Furthermore,
the difference in H3K27me3 expression levels was evalu-
Locoregional progression-free survival curves for total cohort and different subsets of ESCC patients Figure 2
Locoregional progression-free survival curves for total cohort and different subsets of ESCC patients. (A) Total 
patients, (B) T2-3 subset, (C) T4 subset, (D) N0 subset, (E) N1 subset, (F) M0 subset, (G) M1-lym subset, (H) Chemoradiother-
apy effective and (I) chemoradiotherapy resistant subsets: low expression (dashed line), high expression (solid line).BMC Cancer 2009, 9:461 http://www.biomedcentral.com/1471-2407/9/461
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ated to be a better predictor of LPFS when patients are
stratified on the basis of T, N, M status and CRT response.
It has been revealed that H3K27 methylation was medi-
ated by the primary H3K27 methyltransferase, EZH2, a
component of the Polycomb (PcG) complex that is
involved in early carcinogenesis [26]. As aforementioned,
our results showed that H3K27me3 predicted LPFS pre-
dominately in T2-3, N0 and M0 stages of ESCC may partly
support the link between PcG complex and H3K27me3 in
early carcinogenesis. Similar results were also reported in
surgical treated ESCC patients by Ching et al [15]. In our
CRT treated ESCC cohort, we further demonstrated that
H3K27me3 could better stratify LPFS for CRT effective
patients. In addition, ESCC patients with high expression
of H3K27me3 were more likely to present with large
tumor size and advanced T status; such may be at higher
risk to suffer from tumor progression after CRT. Thus, our
findings might be helpful to better understand the heter-
ogeneity in the prognosis of ESCC patients within the
same stages and even with a good response to CRT. Con-
sidering the potentially important role of H3K27me3 as a
biological mechanism in locoregional progression of
ESCC, the examination of H3K27me3 expression by IHC,
therefore, might be used as an additional tool in risk
assessment and therapy optimizing.
With regards to the biologic function of H3K27me3, it has
been observed that, H3K27me3 was linked to PcG-medi-
ated suppression of homeotic box (Hox) genes and mainte-
nance of embryonic stem cell identity [27], whereas
during embryogenesis and stem cell differentiation, con-
sistent with the strong decrease in H3K27me3 levels asso-
ciated with HOX genes expression, the level of EZH2 also
declined [28,29]. Our results supported the role of
H3K27me3 in cell differentiation of ESCC. Since methyl-
ation of H3K27 mediated by EZH2 has been implicated in
the aggressive phenotype of cancer cells through repres-
sion of a panel of tumor suppression genes [30,31], the
loss of function of these genes, in turn, locks stem/precur-
sor cells into abnormal clonal expansion which begins a
process of neoplastic initiation [32,33]. This might pro-
vide a possible explanation for the association of
H3K27me3 expression and local invasion in ESCC found
by our study. Moreover, an imbalance of H3K27 methyl-
ation owing to overexpression of EZH2 has been impli-
cated in metastatic prostate and aggressive breast cancers
[8,9], in which a highly significant overlap between PRC2-
and H3K27me3-occupied genes was observed [8]. To
determine whether there was a potential correlation
between the expression of EZH2 and H3K27me3 in ESCC,
we evaluated the expression status of the two proteins by
IHC in the same cohort of cases. Our results demonstrated
that the expression level of H3K27me3 in high EZH2
expression group was significantly higher than that in low
EZH2 expression group, which supported the view that
Table 3: Multivariate Cox regression analysis for LPFS
LPFS
Variable HRa(95% CIb) P
H3K27me3 expression 0.065
Low 1.000
High 1.568 (0.972-2.528)
CRT response 0.023
Effective 1.000
Resistant 1.820 (1.084-3.055)
T status 0.013
T2-3 1.000
T4 1.376 (1.068-1.772)
M status 0.029
M0 1.000
M1-lym 1.721 (1.056-2.806)
aHazard ratio. bConfidence interval.
Table 2: Univariate analysis of H3K27me3 for LPFS (log-rank 
test)
LPFS (months)
Variables Case Mean Median P-value
Total 0.010
Low expression 53 33.5 20.6
High expression 45 19.4 10.4
T status
T2-3 0.048
Low expression 31 39.4 33.1
High expression 16 25.9 20.0
T4 0.224
Low expression 22 23.6 9.7
High expression 29 12.9 8.6
N status
N0 0.005
Low expression 8 62.5 NRa
High expression 8 11.9 7.4
N1 0.230
Low expression 40 26.2 13.6
High expression 42 20.5 12.7
M status
M0 0.018
Low expression 33 40.8 29.5
High expression 26 22.6 10.4
M1-lym 0.117
Low expression 20 20.5 14.7
High expression 19 13.4 9.9
CRT response
Effective 0.022
Low expression 37 40.2 29.6
High expression 24 24.0 14.1
Resistant 0.715
Low expression 16 14.9 8.6
High expression 21 12.6 8.5
a Not reached.BMC Cancer 2009, 9:461 http://www.biomedcentral.com/1471-2407/9/461
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up-regulated expression of H3K27me3 in ESCCs might be
caused, at least partly, by increased expression of EZH2. In
other types of human cancer, in contrast, Wei et al
reported that loss of H3K27me3 correlated with poor
prognosis of patients with breast, ovarian, and pancreatic
cancers, in which no association was observed between
expression of H3K27me3 and EZH2 [14]. Considering
that the mechanism by which EZH2-mediated H3K27
methylation leads to gene silencing may vary among gene
targets and among organisms [34], discrepancies in differ-
ent studies may arise. In addition, recent studies demon-
strate that the H3K27me3 mark is more dynamic than
previously anticipated and suggest that the levels of
H3K27me3 is fine-tuned by opposing activities: demethy-
lases and the PRC2 complex [27,35]. These results, collec-
tively, suggested that the regulation of H3K27me3
expression is quite complicated and its biologic/clinical
significance in different human cancers may be tissue-spe-
cific. Clearly, further investigations are substantially
needed.
Conclusion
In summary, in this study, we describe protein expression
of H3K27me3 and its correlation with EZH2 expression in
normal human esophageal tissues and in ESCCs. Our
results provided, for the first time, a basis for the concept
that high expression of H3K27me3, as detected by IHC,
might be useful for stratifying LPFS for different subsets of
ESCC patients treated with definitive CRT.
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